Pacific Biosciences of California PACB Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's deferred revenue, net of current portion?
- Pacific Biosciences of California (PACB) reported deferred revenue, net of current portion of $3.55M in Q1 2026.
- How has Pacific Biosciences of California's deferred revenue, net of current portion changed year-over-year?
- Pacific Biosciences of California's deferred revenue, net of current portion decreased by 39.3% year-over-year, from $5.86M to $3.55M.
- What is the long-term trend for Pacific Biosciences of California's deferred revenue, net of current portion?
- Over 5 years (2020 to 2025), Pacific Biosciences of California's deferred revenue, net of current portion has grown at a 20.2% compound annual growth rate (CAGR), from $1.57M to $3.93M.